{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-022802","form_type":"8-K","ticker":"SNDX","cik":"0001395937","company_name":"Syndax Pharmaceuticals Inc","filed_at":"2023-05-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.688502+00:00","generated_at":"2026-06-14T21:03:17.794368+00:00","sec_items":["3.03","5.03","5.07","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Syndax shareholders approve increase in authorized shares from 110M to 210M","bullets":["Amendment to certificate of incorporation increases authorized shares: 200M common stock + 10M preferred stock.","All four proposals passed at May 17, 2023 annual meeting; directors elected with majority support.","Advisory vote on executive compensation passed with 58.1M for vs 0.8M against; auditor ratified.","Increase provides flexibility for potential future equity financings or corporate actions."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-022802","json":"https://secwatch.observer/filing/0000950170-23-022802.json","markdown":"https://secwatch.observer/filing/0000950170-23-022802.md","text":"https://secwatch.observer/filing/0000950170-23-022802.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1395937/000095017023022802/0000950170-23-022802-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1395937/000095017023022802/sndx-20230517.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T21:03:17.794368+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b184cce472e6379939d79e51203e8c35323baa6b","claim":"Syndax Pharmaceuticals Inc: Increased authorized shares from 110,000,000 to 210,000,000, consisting of 200,000,000 common shares and 10,000,000 preferred shares (effective 2023-05-17).","evidence_excerpt":"On May 17, 2023, following receipt of the affirmative vote from the holders of a majority of the outstanding shares of common stock of Syndax Pharmaceuticals, Inc. (the “ Company ”) at the Annual Meeting (as defined below), the Company filed a certificate of amendment to the Company’s amended and restated certificate of incorporation (the “ Certificate Amendment ”) with the Secretary of State of the State of Delaware to increase the authorized number of total shares of all classes of stock that the Company has authority to issue from 110,000,000 shares to 210,000,000 shares, consisting of two classes: (1) 200,000,000 shares of common stock, $0.0001 par value per share, and (2) 10,000,000 shares of preferred stock, $0.001 par value per share. The Certificate Amendment became effective immediately upon filing.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1395937/000095017023022802/0000950170-23-022802-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2023-05-17"}],"fact_type":"governance_change"},{"claim_id":"1f6501b64cf5e8acf76f457eec86d771c9375df1","claim":"Syndax Pharmaceuticals Inc shareholders approved Approval of amendment to the Company’s amended and restated certificate of incorporation to increase the number of authorized shares of common stock at the 2023-05-17 meeting.","evidence_excerpt":"Proposal 4 : Approval of amendment to the Company’s amended and restated certificate of incorporation to increase the number of authorized shares of common stock: For Against Abstain Broker Non-Votes 62,460,712 675,568 6,907 —","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1395937/000095017023022802/0000950170-23-022802-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"charter amendment"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-05-17"}],"fact_type":"shareholder_vote"},{"claim_id":"209891eaea91e205f88bc8bb325c6a368b433d41","claim":"Syndax Pharmaceuticals Inc shareholders approved Advisory vote on executive compensation at the 2023-05-17 meeting.","evidence_excerpt":"Proposal 2 : Advisory vote on executive compensation: For Against Abstain Broker Non-Votes 58,132,013 787,719 8,890 4,214,565","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1395937/000095017023022802/0000950170-23-022802-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-05-17"}],"fact_type":"shareholder_vote"},{"claim_id":"59d3fc30a539708c1bc45c8f7ee228f92dd19101","claim":"Syndax Pharmaceuticals Inc shareholders approved Election of directors at the 2023-05-17 meeting.","evidence_excerpt":"Proposal 1 : Election of directors: Nominee For Withheld Broker Non-Votes Pierre Legault 35,300,479 23,628,143 4,214,565 Michael A. Metzger 57,418,793 1,509,829 4,214,565","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1395937/000095017023022802/0000950170-23-022802-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-05-17"}],"fact_type":"shareholder_vote"},{"claim_id":"b099a25b9f5ffa0b292f4bad0a74d2caf2ce618f","claim":"Syndax Pharmaceuticals Inc shareholders approved Ratification of selection of independent registered public accounting firm at the 2023-05-17 meeting.","evidence_excerpt":"Proposal 3 : Ratification of selection of independent registered public accounting firm: For Against Abstain Broker Non-Votes 63,037,788 103,402 1,997 —","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1395937/000095017023022802/0000950170-23-022802-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-05-17"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}